On Wednesday, the FDA accepted GSK plc’s (NYSE:GSK) marketing application seeking approval for gepotidacin, an ...

The FDA has started a priority review of GSK's gepotidacin, which could become the first in a new class of oral antibiotics ...

Application supported by positive results from pivotal phase III EAGLE-2 and EAGLE-3 trials26 March 2025 assigned as action date for FDA decisionGepotidacin could be the first in a new class of oral ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

GSK plc (GSK, GSK.L) announced the FDA has accepted the New Drug Application for gepotidacin, an oral antibiotic with a mechanism of ...

(Alliance News) - GSK PLC on Wednesday announced that the US Food & Drug Administration has accepted its New Drug Application for gepotidacin. The London-based biopharma company said the FDA has ...

New data to be shared on GSK’s RSV vaccine across different age groups of patients at increased risk • Efficacy data for gepotidacin in ...

GSK announced on Wednesday that the US Food and Drug Administration (FDA) has accepted its new drug application (NDA) for gepotidacin, a first-in-class oral antibiotic, under priority review.

GSK has reported topline results from a phase 3 trial of its novel antibiotic gepotidacin that could spell the end of a decades-long drought in new oral therapies for gonorrhoea. In the EAGLE-1 ...

GSK & ViiV Healthcare to showcase advances across industry-leading infectious disease portfolio at IDWeek 2024: London, UK Monday, October 14, 2024, 14:00 Hrs [IST] GSK plc and Vi ...

London open The FTSE 100 is expected to open 17 points higher on Wednesday, having closed down 0.52% on Tuesday at 8,249.28.

GSK said that its urinary tract infections treatment gepotidacin has been accepted for priority review by the U.S.'s Food and Drug Administration.